Pfizer-BioNTech COVID-19 Bivalent Vaccine Booster Authorized for Use in Individuals Aged Six Months to Four Years

Mar 28, 2023

In a March 14, 2023 announcement, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the use of Bivalent COVID-19 Vaccines from Pfizer- BioNTech to be used as a booster dose for infants and children ages six months to four years.     

The Office of MaineCare Services (OMS) will update our system to include the code listed in the table below. IMPORTANT: Please hold all  COVID-19 vaccine claims administration for this age group until this system update is complete. We will notify you when the system is updated. 

  

Pfizer-BioNTech COVID-19 Bivalent Vaccine Booster - 6 months to 4 years
Code	Description	Effective Date	MaineCare Rate
0174A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose	03/14/23	TBD*
*Rate for this code is not yet established    Note: The COVID-19 vaccine administration codes will be added for roster billing.

  

Providers may visit the Maine CDC Immunization Program Website for up-to-date information on administering and ordering COVID-19 vaccine and booster doses.   

If you have questions about the use of Monovalent or Bivalent COVID-19 vaccines, please contact your Provider Relations Specialist.